|
Switch from lamivudine to adefovir |
|
AIM: To compare the antiviral efficacy of adefovir ADV ; in lamivudine LMV ; -resistant patients with LMV treatment in nucleoside-nave patients, using serum samples collected sequentially during the course of treatment progressing from LMV to ADV. METHODS: Forty-four patients with chronic hepatitis B CHB ; were included. The patients were initially treated with LMV and then switched to ADV when LMV resistance developed. Antiviral efficacy was assessed by measuring the following: reduction in serum HBV DNA from baseline, HBV DNA negative conversion defined as HBV DNA being undectable by the hybridization assay ; , 5 and HBV DNA response either HBV DNA level 10 copies mL or a log10 reduction from baseline HBV DNA level ; . RESULTS: After two and six months of treatment, HBV DNA reduction was greater with LMV compared to ADV treatment P 0.021 ; . HBV DNA negative conversion rates were 64% and 27% after one month of LMV and ADV treatment respectively P 0.001 ; . Similarly, HBV DNA response rates were 74% and 51% after two months of LMV and ADV treatment respectively P 0.026 ; . The time taken to HBV DNA negative conversion and to HBV DNA response were both delayed in ADV treatment compared with LMV. CONCLUSION: The antiviral efficacy of ADV in LMVresistant patients is slower and less potent than that with LMV in nucleoside-nave patients during the early course of treatment.
Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium and 2Centre for Veterinary Science, University of Cambridge, Madingley Road, Cambridge CB3 0ES Following the discovery of the first effective antiviral compound idoxuridine ; in 1959, nucleoside analogues, especially acyclovir ACV ; for the treatment of herpesvirus infections, have dominated antiviral therapy for several decades. However, ACV and similar acyclic nucleosides suffer from low aqueous solubility and low bioavailability following oral administration. Derivatives of acyclic nucleosides, typically esters, were developed to overcome this problem and valaciclovir, the valine ester of ACV, was among the first of a new series of compounds that were readily metabolized upon oral administration to produce the antiviral nucleoside in vivo, thus increasing the bioavailility by several fold. Concurrently, famciclovir was developed as an oral formulation of penciclovir. These antiviral `prodrugs' thus established a principle that has led to many successful drugs including both nucleoside and nucleotide analogues for the control of several virus infections, notably those caused by herpes-, retro- and hepatitisviruses. This review will chart the origins and development of the most important of the antiviral prodrugs to date. British Journal of Pharmacology 2006 ; 147, 111. doi: 10.1038 sj.bjp.0706446; published online 14 November 2005 Antiviral prodrugs; famciclovir; valaciclovir; valganciclovir; cidofovir prodrugs; adefovir prodrug; tenofovir prodrug ACV, acyclovir; AZT, azidothymidine; BVDU, bromovinyldeoxyuridine; cCDV, cHPMPC, cyclic cidofovir; CMV, cytomegalovirus; ddC, dideoxycytidine; ddI, dideoxyinosine; d4T, didehydrodideoxythymidine; DP, diphosphate; FddGuo, FLG, 30 -fluoro-20 , 30 -dideoxyguanosine; FddThd, FLT, 30 -fluoro-20 , 30 -dideoxythymidine FTC, emtricitabine; GCV, ganciclovir; HBV, hepatitis B virus; 30 -Val-L-dC, 30 -valine ester of L-dC valtorcitabine HDP-CDV, hexadecyloxypropyl cidofovir; HDP-cCDV, hexadecyloxypropyl cyclic ; cidofovir; HPMPC, cidofovir, S ; -1- ; cytosine; HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2; H2G, ; -9-[4-hydroxy-2- hydroxymethyl ; butyl]guanine ; -2HM-HBG ; L-dC, b-L-20 -deoxycytidine; L-dT, b-L-thymidine; MP, monophosphate; MIV-606, L-valine, 3R ; -3[2-amino-1, 1-oxooctadecyl ; oxo]butylester; MIV-210, bis 5'-O-[ S ; -2- L-valoyloxy ; propionyl ; -FLG; NANA, N-acetylneuraminic acid; ODE-cCDV, octadecyloxyethyl cyclic ; cidofovir; ODE-CDV, octadecyloxyethyl cidofovir; PCV, penciclovir; PMEA, adefovir, 9- 2-phosphonylmethoxyethyl ; adenine; PMPA, tenofovir, R ; -9- 2-phosphonylmethoxypropyl ; adenine; TDF, tenofovir disoproxil fumarate; TK, thymidine kinase; TP, triphosphate; VZV, varicella-zoster virus.
Adefovir more drug_uses
Management of AIDS, 6th ed., W.B. Saunders Company, Philadelphia, 1999, pp. 343-352. Current ; Sande MA, Eliopoulos GM, Moellering RC, Gilbert DN eds ; . The Sanford Guide To HIV AIDS Therapy 2005, 14th edition. Sperryville, Virginia: Antimicrobial Therapy, Inc., 2005 Beatrice B. Turkoski, et al., Drug Information Handbook for Advanced Practice Nursing, 7th ed., Lexi-Comp, Inc., Hudson, Ohio, 2006. Kenneth Zwolski and Dorothy Talotta, "Bacterial Infections, " in Carl A. Kirton, et al. eds. ; , Handbook of HIV AIDS Nursing, Mosby, St Louis, 2001, pp. 230-235. Current.
Chem. Listy 97, 81 82 ; mou Gilead Sciences. Organizace a finann a materilov zabezpeen vech fz klinickch zkouek jsou obecn natolik finann nron a pitom rizikov, e nebylo mon hledat spolupracujc farmaceutickou firmu v esk republice. V ppad adefoviru se jasn projevila mra rizika, kter mus farmaceutick firma vyvjejc nov prepart unst. Adefovir byl pvodn uvaovn jako prostedek pro len AIDS. Vechny etapy testovn probhly spn a a v zvren fzi se ukzalo, e u nkterch pacient vyvolvaj potebn dvky lku nedouc vedlej reakce. Prepart byl proto z klinickch zkouek staen a dosud vynaloen sil a finann prostedky se zdly bt ztracen. Jen dky komplexnmu studiu jeho antivirov aktivity byl prepart pekvalifikovn a spn proel vemi etapami zkouek jako lk proti hepatitid B. Zvren oteven klinick zkouky podle psnho protokolu provedla firma Gilead Sciences u 2000 pacient s jednoznan kladnm vsledkem.Vhoda toto lku spov v jeho innosti i pi len chronick formy tohoto onemocnn, kdy se asto vytv u pacient mutantn HBV viry, rezistentn vi dosud nejspnjmu prepartu lamivudinu. V dsledku vysok innosti proti viru hepatitidy B postauje jeho mal dvkovn, kter pacienty nezatuje, a nedouc vedlej inky jsou tak minimalizovny. Ani po 48 tdenn terapii nebyl zjitn vskyt mutantnho viru rezistentnho vi novmu lku. Objevitelsk vklad Dr. A. Holho, jeho kolektivu na praskm akademickm stavu a spolupracujcch belgickch koleg byl silm pracovnk Gilead Sciences vysoce zhodnocen. Vechny ti ltky, kter byly ji na potku spoluprce vybrny pro dal vvoj, se staly zkladem lk proti nebezpenm virovm chorobm. Tuto skutenost hodnot Dr. A. Hol jako mimodn spch podmnn astnou volbou partnersk farmaceutick firmy. Tato spn spoluprce m i podstatn ekonomick efekt ve form licennch poplatk, kter dostv stav organick chemie a biochemie a formou dan i esk stt. Dky tmto.
Recombinant viruses remained resistant to a lower level ; to GCV as well as to the other DNA pol inhibitors previously mentioned 89, 121 ; . The plaque-purified clinical isolate exhibited GCV resistance in the presence of wild-type levels of GCV phosphorylation. The mutant was also resistant to CDV, adefovir, and FOS, which strongly suggested that the target of all those antivirals the DNA pol ; was the site of the alteration 124 ; . From the mutations reported thus far, some conclusions on the regions involved in drug resistance can be drawn. In general, mutations located within the Exo I motif, region IV including Exo II ; , the N-terminal extremity of region C including Exo III ; , and region V are mostly associated with resistance to GCV and CDV. On the other hand, mutations located within the C-terminal extremity of region C and within or next to conserved regions II and VI seem to be mostly involved in FOS resistance. Finally, mutations reported within or next to conserved region III appear to be associated with various drug resistance or hypersusceptibility phenotypes Fig. 3 ; . It would therefore be tempting to define binding sites for dNTPs and pyrophosphates on the basis of the distribution of those HCMV mutations. However, the distribution of mutations affecting susceptibilities to adefovir and lobucavir two other nucleotide or nucleoside analogues ; 37 ; as well as the drug phenotypes associated with mutations in the same conserved regions of HSV and varicella-zoster virus DNA pol genes 53 ; preclude such conclusions from being made. This probably reflects the complex folding of the protein, which brings together distant conserved regions to form the specific binding sites, and definitive conclusions should await protein crystallization. Readers are referred to Fig. 3 and to a recent review 53 ; for an extensive list of DNA pol mutations associ.
Adefovir pharmacy
Rheumatoid arthritis is the most common inflamematory joint disease which presents with symmetrical polyarthritis of hands with inflammatory behavior, and extra artricular manifestations. The disease initially involves synovium membrane of joints. The disease prevalence is about 1 percent so 700000 of 70000000 population in Iran have rheumatoid arthritis and severe disability will result with delay in diagnosis and treatment. Despite of effects on life quality, rheumatoid arthritis has direct and indirect effects on patients and their society and adriamycin.
Capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J. Biol. Chem. 279: 2548925496. 8. Deval, J., B. Selmi, J. Boretto, M. P. Egloff, C. Guerreiro, S. Sarfati, and B. Canard. 2002. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J. Biol. Chem. 277: 4209742104. 9. Deval, J., K. L. White, M. D. Miller, N. T. Parkin, J. Courcambeck, P. Halfon, B. Selmi, J. Boretto, and B. Canard. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279: 509516. 10. Feng, J. Y., and K. S. Anderson. 1999. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant 184V ; of HIV-1 reverse transcriptase. Biochemistry 38: 94409448. 11. Feng, J. Y., F. T. Myrick, N. A. Margot, G. B. Mulamba, L. Rimsky, K. Borroto-Esoda, B. Selmi, and B. Canard. 2006. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151m-associated HIV-1 drug resistance towards emtricitabine and lamivudine. Nucleosides Nucleotides Nucleic Acids 25: 89107. 12. Hammond, J. L., U. M. Parikh, D. L. Koontz, S. Schlueter-Wirtz, C. K. Chu, H. Z. Bazmi, R. F. Schinazi, and J. W. Mellors. 2005. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2 , 3 -didehydro-2 , 3 -dideoxy-5-fluorocytidine. Antimicrob. Agents Chemother. 49: 39303932. 13. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282: 16691675. 14. Jeffrey, J. L., J. Y. Feng, C. C. Qi, K. S. Anderson, and P. A. Furman. 2003. Dioxolane guanosine 5 -triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and presteady state kinetic analyses. J. Biol. Chem. 278: 1897118979. 15. Johnson, K. A. 1995. Rapid quench kinetic analysis of polymerases, adenosinetriphosphatases, and enzyme intermediates. Methods Enzymol. 249: 3861. 16. Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, A. Telenti, and D. D. Richman. 2005. Update of the drug resistance mutations in HIV-1: fall 2005. Top. HIV Med. 13: 125131. 16a.Kagan, R., L. Ross, M. Winters, T. Merigan, P. Heseltine, and M. Lewinski. 2005. Adefovir-associated HIV-1 RT mutation K70E in the age of tenofovir. Antivir. Ther. 10: S103. 17. Kagan, R. M., T. C. Merigan, M. A. Winters, and P. N. Heseltine. 2004. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization. Antivir. Ther. 9: 827828. 18. Kati, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267: 25988 25997. Le Grice, S. F., C. E. Cameron, and S. J. Benkovic. 1995. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262: 130144. 20. Le Grice, S. F., and F. Gruninger-Leitch. 1990. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 187: 307314. 20a.Lloyd, R., J. Huong, E. Rouse, P. Gerondelis, M. Lim, M. Shaefer, A. Rodriguez, J. Gallant, R. Lanier, and L. L. Ross. 2005. HIV-1 RT mutations K70E and K65R are not present on the same viral genome when both mutations are detected in plasma, abstr. 1066. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. 21. Meyer, P. R., S. E. Matsuura, A. M. Mian, A. G. So, and W. A. Scott. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4: 3543. 22. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95: 1347113476. 23. Miller, M. D., K. E. Anton, A. S. Mulato, P. D. Lamy, and J. M. Cherrington. 1999. Human immunodeficiency virus type 1 expressing the lamivudineassociated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. 179: 92100. 24. Mulato, A. S., P. D. Lamy, M. D. Miller, W. X. Li, K. E. Anton, N. S. Hellmann, and J. M. Cherrington. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob. Agents Chemother. 42: 16201628. 24a.Parikh, U. M., N. Sluis-Cremer, and J. W. Mellors. 2005. Kinetic mechanism by which thymidine analog mutations antagonize K65R in HIV-1 reverse transcriptase. Antivir. Ther. 10: S95. 25. Parikh, U. M., L. Bacheler, D. Koontz, and J. W. Mellors. 2006. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J. Virol. 80: 49714977. 25a.Ross, L., P. Gerondelis, Q. Liao, B. Wine, M. Lim, M. Shaefer, A. Rodriguez.
Adefovir hiv
Adefovir became an approved treatment for hbv in the united states in september 2002 and in the european union in march 200 mechanism of action adefovir works by blocking reverse transcriptase , an enzyme that is crucial for the hepatitis b virus hbv ; to reproduce in the body and agenerase.
If HBV infection is to be treated without concurrent antiretroviral therapy eg, in patients who have not yet started antiretroviral therapy ; , drugs that are not active against HIV should be used to prevent development of drug-resistant HIV. Peginterferon alfa is an option; it may be most useful in patients who are HBeAg-positive, have HBV genotype A, and have elevated ALT. Adefovir is another option. Published data do not show activity of entecavir against HIV, so that is another option.
The homepage has links to all the information contained on the site, either through the menu bar or directly to the exercises. The introductory text was changed three time during the pilot, the first time alerting users that the site was being evaluated, the second time asking for feedback on content and the third time alerting users that the updated site would soon be ready and aggrenox.
11. Gmez- Flores A., 0. Welsh, S. Said-Fernndez, G. Lozano-Garza, R. E. Tavarez-Alejandro, and L. Vera-Cabrera. 2004. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob. Agents Chemother. 12. Laurent, F. J. , F. Provost, and P. Boiron. 1999. Rapid identification of.
Email your suggestions or questions i'd love to hear from you and alefacept.
The data show that viread is non-inferior to the company's once-daily antiviral drug hepsera r ; adefovir dipivoxil ; among patients with e antigen hbeag ; -positive chronic.
Experimental conditions and results of the RAFT polymerization of tBuA; Mn, GPC obtained using poly tert-butyl acrylate ; calibration. For abbreviations see Tab. 4.2 and aleve.
HCV RNA post-transplant, of which six 75% ; developed clinical recurrence with elevated transaminases and compatible histology. Five patients received anti-viral treatment but three stopped treatment after one, 14 and 20 weeks respectively, due to adverse effects in two, and recurrence of HCC in one patient. Two patients completed 12 months of standard interferon and ribavarin and both achieved end of follow-up virological response, representing a cure of their HCV. When comparing the survival between those with and without chronic viral hepatitis, the two- and four-year survival rates between those transplanted for chronic viral hepatitis B or C were 81% and 81%, respectively, which was similar to those of adult patients transplanted for other indications 76% and 70%, respectively, p 0.42 ; . DISCUSSION Our study showed that CHB- and CHC-related liver disease constituted 57% of all indications for adult liver transplants in Singapore. The high prevalence was not surprising, as chronic hepatitis B is endemic in Singapore with 4.1% of carrier rate, and complications develop in 10-40% of patients with chronic hepatitis B 11 ; . Long-term survivals for both conditions post-transplant are reasonable at 68% and 76%, respectively, and are comparable with results in major centres in the USA and Europe 12, 13 ; . Our results showed that our current strategy of antiviral prophylaxis of lamivudine monotherapy pre- and post-transplant, followed by adefovir dipivoxil when lamivudine resistance occurs, is effective. With the use of prophylactic lamivudine, none of the liver transplant recipients developed fibrosing cholestatic hepatitis after liver transplant.
Adefovir 10 mg
And, while we have not yet experienced kidney toxicity in our clinical trials of tenofovir df, the kidney toxicity in our clinical trials of adefovir dipivoxil for aids did not arise until the later stages of our clinical trials and alfuzosin.
ANNEX 2 to CPMP Monthly Report March 2003 MEDICINAL PRODUCTS GRANTED A COMMUNITY MARKETING AUTHORISATION UNDER THE CENTRALISED PROCEDURE SINCE FEBRUARY 2003 CPMP MONTHLY REPORT Vivanza vardenafil Bayer AG G04B E09 Treatment of erectile dysfunction 21.11.2002 Levitra vardenafil Bayer AG G04B E09 Treatment of erectile dysfunction 21.11.2002 Hepsera adefovir dipivoxil Gilead Science International Limited pending Treatment of chronic hepatitis B in adults 21.11.2002 and adefovir.
The images reported here show with great detail the atomic structure and topography of a natural 010 ; cleavWith the advent of scanning tunneling microscopy STM ; Binnig et al., 1982 ; and atomic force microscopy agesurface.The goal of this study is to determine whether AFM ; Binnig et al., 1986 ; , scientistsin a variety of dis- the surfaceis an ideal termination of the bulk structure. ciplines have been able to obtain unprecedentedinfor- We baseour results on a comparison of measuredsurface mation on the atomic-scale structure and topography of orientations and nearestneighbor distancesfrom the AFM surfaces.In the field of mineralogy, nearly all surface images with those from a surfaceprojection of the bulk AFM-STM studies to date have imaged structurally sim- structure, as deducedfrom X-ray and neutron diffraction ple minerals that cleavealong well-definedatomic planes. data in the literature. From this comparison, we note that Two very recent studies have focused on framework there is no evidence for surface reconstruction, and in silicate minerals, quartz and albite. Gratz et al. 1991 ; general terms, the correspondencebetween the surface investigatedthe development of etch pits and the move- and bulk structures is very close. The largest measured ment of atomic-scale ledges during the dissolution of differencesin nearestneighbor distanceswas 0.2-0.4 A. quarlz. Hochella et al. 1990 ; studied the surfaceof albite The measureddifferencesmay be due to a variety of reasons, as we discusslater on. both with AFM and low-energy electron difraction LEED ; . Their AFM imagesreveal the presence nanoof ExpBmNrnNr, q.L meter-sized surface pits and depressions.Both of these microscope studiesdid not achieveatomic-scaleresolution, however. Atomic force In this paper we use AFM images to determine the The NanoScope II contact mode AFM from Digital atomic-scale surface structure and topography of the 010 ; Instruments used in this experiment is based on an opplane of albite. We have chosenalbite for AFM imaging tical lever design Meyer and Amer, 1988; Alexander et for two main reasons: its general geological importance al., 1989 ; that has been described in detail in previous in the Earth's crust and the fact that its bulk structure is publications Ruger and Hansma, 1990 ; . In this study well known. In addition, the chemical and structural evo- imaging forces ranged from l0 to 100 nN using l2o-pm lution of the near-surfaceregion after alteration has been SirNo cantilevers from Digital Instruments ft 0.6 N studied with a variety of spectroscopictechniques, both m ; with integral tips. Lower forces can be used, but imfor albite Hellmann et al., 1990 ; , and other feldspars proved image quality is usually obtained on rigid crys Caseyet al., 1989 ; .Thus, this presentstudy should serve talline materials at higher forces. The AFM can operate as a basis for providing new and complementary infor- under a variety of fluids; however, the images presented mation on the surface structure and reactivitv of albite here were all taken in air using a piezotranslator with a surfaces. s c a This study utilized low albite from Amelia Court House, * To whom correspondence should be addressed. Viryinia; it was supplied by Wards Scientific EstablishINrnooucrroN and alimta.
Adefovir diphosphate
The improvement in histologic liver abnormalities and the absence of resistance mutations suggest that ade- This study demonstrates that adefovir dipivoxil is fovir dipivoxil may prove helpful for patients with chron- effective for HBeAg-positive chronic hepatitis B. The ic hepatitis B who require long-term antiviral therapy. study did not compare adefovir dipivoxil with other therapies, nor did it assess whether long-term treatsee page 800; editorial, page 848 ment is effective.
Adefovir tenofovir
Sustiva more drug_side_effects, bronchus hilus, board eligible orthodontist, abscission hormones and ramipril nhs direct. Granuloma of pregnancy, aspartic acid asparagus, ewing sarcoma charity and do i have agoraphobia quiz or splenomegaly sickle cell.
Adefovir
Axefovir, adevovir, asefovir, wdefovir, adefvoir, adefocir, adecovir, adefovi5, adefoir, adefovri, adefovit, adefovlr, addefovir, adfovir, adef9vir, adwfovir, aderovir, adefoovir, adefovirr, adefogir.
Adefovir hepatitis
Adefovir more drug_uses, adefovir pharmacy, adefovir hiv, adefovir 10 mg and adefovir diphosphate. Adefovir tenofovir, adefovir, adefovir hepatitis and adefovir hbv or adefovir adv.
|
|
|
